natgillin/translations-raw huggingface dataset:
Basisvaccination: To doser af Versican Plus L4 med 3 til 4 ugers mellemrum fra 6-ugers alderen.
Primary vaccination scheme: Two doses of Versican Plus L4 3–4 weeks apart from 6 weeks of age.
Basisvaccination: To doser af Versican Plus Pi/L4 med 3 til 4 ugers mellemrum fra 6-ugers alderen.
Primary vaccination scheme: Two doses of Versican Plus Pi/L4 3–4 weeks apart from 6 weeks of age.
Basisvaccination: To doser af Versican Plus Pi/L4R med 3 til 4 ugers mellemrum fra 8-9-ugers alderen.
Primary vaccination scheme: Two doses of Versican Plus Pi/L4R 3-4 weeks apart from 8-9 weeks of age.
Basisvaccination: to injektioner med et interval på 21 dage.
Basic vaccination: two injections 21 days apart.
BASP = basisk fosfatase, CI = konfidensinterval, NE = kan ikke estimeres, PSA = prostataspecifikt antigen,
ALP = alkaline phosphatase; CI = confidence interval; NE = not estimable; PSA = prostate-specific antigen;
BAT blev bestemt af investigatoren fra patient til patient og inkluderede hydroxycarbamid (59,5%), interferon/pegyleret interferon (11,7%), anagrelid (7,2%), pipobroman (1,8%) og observation (15,3%).
BAT was selected by the investigator on a patient-by- patient basis and included hydroxyurea (59.5%), interferon/pegylated interferon (11.7%), anagrelide (7.2%), pipobroman (1.8%) and observation (15.3%).
Batch
Batch {number}
Batch
Batch.
Batch
Batch:
Batch : {nummer}
Batch {number}
Batch : {nummer}
BN : {number}
Batch nr. {nummer}
<Lot> {number}
Batch nr. {nummer}
Lot {number}
Batch nummer
Batch {number}
BATCH NUMMER
MANUFACTURER’S BATCH NUMBER
Batch Solvensbatch
Batch Solvent Batch
Batch {nummer}
BN {number}
Batch {nummer}
BN{number}
Batch, {nummer}
Lot {number}
Batch.
Lot.
Batch.:
Batch:
Batch/Lot {nummer}
Lot {number}
Batch:
Batch :
Batch:
Batch number.
Batch:
BN:
Batch: ...
Batch: ......
Batch: ...
Batch: .......
Batch: Patientkode:
Batch: Patient code:
Batch: Patientkode: Donorkode:
Batch: Patient code: Donor code:
Batch: {nummer}
BN: {number}
Batch: {nummer}
Lot: {number}
Batch: {nummer}
Lot:{number}
BATCHFRIGIVELSE
BATCH RELEASE
Batchnr
Lot
Batchnr.:
Batch
BATCHNUMBER
BATCH NUMBER
Batchnummer
Batch number:
Batchnummer
Batch:
BATCHNUMMER
BATCHN UMBER
Batchnummer
Lot: {number}
BATCHNUMMER
MARKETING AUTHORISATION NUMBER
BATCHNUMMER
STORAGE CONDITIONS
Batchnummer:
Batch number.
Batchnummer:
Batch Number:
Batchnummer: Behandlingsdato: Lægens navn: Lægens tlf.nr.: Patientkodenummer:
Doctor Phone: Patient Code number:
Batchnummer: {XXXXX}
Batch N°: {XXXXX}
Batch{nummer}
BN{number}
BATTERI-symbol
COUNTDOWN-CLOCK symbol
Batteriet er ved at være opbrugt.
The countdown-clock is counting downwards.
Batteriet holder typisk 24 måneder og virker i 4 uger efter første gang, ‘bt’ begynder at blinke.
Batteries typically last 24 months and have a 4-week life from the time the „bt‟ first starts blinking.
Bavarian Nordic A/S Hejreskovvej 10A, 3490 Kvistgaard Danmark
Bavarian Nordic A/S Hejreskovvej 10A, 3490 Kvistgaard Denmark
Baxalta Belgium Manufacturing SA Boulevard René Branquart 80
Baxalta Belgium Manufacturing SA Boulevard René Branquart, 80
Baxalta Belgium Manufacturing SA Boulevard René Branquart, 80
Baxalta Belgium Manufacturing SA Boulevard René Branquart 80
Baxalta Denmark A/S Tlf.: +45 32 70 12 00
Baxalta Denmark A/S Tlf: +45 32 70 12 00
Baxalta Innovations GmbH A-1221 Wien
Baxalta Innovations GmbH A-1221 Vienna
Baxalta Norway AS Tlf.: +47 22 585 000
Baxalta Norway AS Tlf: +47 22 585 000
BAXJECT II-devicet må ikke anvendes, hvis det sterile filter eller pakningen er beskadiget eller viser tegn på nedbrydning.
Do not use if the BAXJECT II device, its sterile barrier system or its packaging is damaged or shows any sign of deterioration.
Baxter AG Industriestrasse 67 A - 1221 Wien Østrig
Baxter AG Industriestrasse 67 A-1221 Vienna Austria
Baxter AG Industriestrasse 67 A-1221 Wien Østrig
Baxter AG Industriestrasse 67 A-1221 Vienna
Bayer [Logo]
Bayer (Logo)
Bayer A/SAnimal Health Arne Jacobsens Allé 13
Bayer A/S Animal Health
Bayer Austria Ges. m. b.
Bayer d.o.o.
Bayer B.V.
Bayer OÜ
Bayer d.o.o.
Bayer AS
Bayer HealthCare LLC 800 Dwight Way Berkeley
800 Dwight Way,
Bayer Hispania, S.L.
Bayer Hispania, S.L. Av.
Bayer Limited, Animal HealthThe Atrium, Blackthorn Road
Bayer Limited, Animal Health The Atrium,
Bayer Logo
Bayer-Logo
Bayer Pharma AG 13342 Berlin Tyskland
Bayer Pharma AG 13342 Berlin Germany
Bayer Pharma AG 13342 Berlin Tyskland
Bayer Pharma AG D-13342 Berlin Germany
Bayer Pharma AG 51368 Leverkusen Tyskland
Bayer Pharma AG 51368 Leverkusen Germany
Bayer Pharma AG D-13342 Berlin Tyskland
Bayer Pharma AG D-13342 Berlin Germany
Bayer Pharma AG D-13342 Berlin Tyskland.
Bayer Pharma AG D-13342 Berlin Germany
Bayer Pharma AG Kaiser-Wilhelm-Allee 51368 Leverkusen Tyskland
Kaiser-Wilhelm-Allee 51368 Leverkusen Germany
Bayer Portugal Lda.
Bayer B.V.
Bayer Portugal, Lda.
Bayer B.V.
Bayer Schering Pharma AG 51368 Leverkusen Tyskland
Bayer Pharma AG 51368 Leverkusen Germany
Bayer Schering Pharma AG D-13342 Berlin
Bayer Schering Pharma AG D – 13342 Berlin
Bayer Schering Pharma AG Müllerstraße 178
Bayer Schering Pharma AG Müllerstrasse 178
Bayer Sp. z o.o.
Bayer S.p.A.
Bayer til injektionsvæske, anvendelse opløsning
for solution for injection
Bazedoxifen er stærkt bundet (98 % - 99 %) til plasmaproteiner in vitro, men bindes ikke til kønshormonbindende globulin (SHBG).
Bazedoxifene is highly bound (98% - 99%) to plasma proteins in vitro, but does not bind to sex hormone binding globulin (SHBG).
Bazedoxifen forårsagede corticomedullær nefrokalcinose og forstærkede spontan kronisk progressiv nefropati (CPN) hos hanrotter.
Bazedoxifene caused corticomedullar nephrocalcinosis and enhanced spontaneous chronic progressive nephropathy (CPN) in male rats.
Bazedoxifen hverken øger eller hæmmer aktiviteten af væsentlige CYP-isoenzymer, og interagerer formentlig ikke med samtidigt anvendte lægemidler via CYP-medieret metabolisme.
Bazedoxifene does not induce or inhibit the activities of major CYP isoenzymes, and is unlikely to interact with co- administered medicinal products via CYP-mediated metabolism.
Bazedoxifen metaboliseres af uridin-diphosphat-glukuronosyltransferase-enzymer (UGT-enzymer) i tarmkanalen og leveren (se pkt.
Bazedoxifene undergoes metabolism by uridine diphosphate glucuronosyltransferase (UGT) enzymes in the intestinal tract and liver (see section 5.2).
Bazedoxifen metaboliseres af uridindiphosphat-glukuronosyltransferase (UGT) –enzymer i tarmen og leveren (se pkt 5.2).
Bazedoxifene undergoes metabolism by uridine diphosphate glucuronosyltransferase (UGT) enzymes in the intestinal tract and liver (see section 5.2).
Bazedoxifen metaboliseres i udtalt grad hos kvinder.
Bazedoxifene is extensively metabolised in women.
Bazedoxifen tilhører en klasse af stoffer, der går under betegnelsen selektive østrogenreceptor- modulatorer (SERM).
Bazedoxifene belongs to a class of compounds known as selective estrogen receptor modulators (SERMs).
Bazedoxifen undergår går kun ringe eller ingen cytochrom P450 (CYP-medieret) metabolisme.
Bazedoxifene undergoes little or no cytochrome P450 (CYP)-mediated metabolism.
Bazedoxifen var ikke genotoksisk eller mutagent i en række test, herunder bakteriel omvendt mutationsanalyse in vitro, fremadrettet mutationsanalyse in vitro med celler fra pattedyr på thymidinkinase (TK±) locus i L5178Y-lymfomceller fra mus, kromosom-aberrationsanalyse in vitro på ovarieceller fra kinesisk hamster (CHO), og mikronukleusanalyse in vivo på mus.
Bazedoxifene was not genotoxic or mutagenic in a battery of tests, including in vitro bacterial reverse mutation assay, in vitro mammalian cell forward mutation assay at the thymidine kinase (TK/-) locus in L5178Y mouse lymphoma cells, in vitro chromosome aberration assay in Chinese hamster ovary (CHO) cells, and in vivo mouse micronucleus assay.
Bazedoxifen virker som en østrogenreceptor “agonist” (et stof, som stimulerer østrogenreceptoren) i visse former for kropsvæv.
Bazedoxifene acts as an ‘agonist’ of the oestrogen receptor (a substance that stimulates the receptor for oestrogen) in some tissues in the body.
Bazedoxifen-clearance er 0,4 ± 0,1 l/t/kg baseret på intravenøs administration.
The clearance of bazedoxifene is 0.4 ±0.1 L/h/kg based on IV administration.
Bazedoxifens farmakokinetik er ikke blevet undersøgt hos den pædiatriske population.
The pharmacokinetics of bazedoxifene have not been studied in the paediatric population.
BCIRG 006-studiet var designet til at undersøge kombinationen af Herceptin-behandling med docetaxel efter AC-kemoterapi eller i kombination med docetaxel og carboplatin hos patienter med HER2-positiv tidlig brystkræft efter operation.
Study BCIRG 006 study was designed to investigate combining Herceptin treatment with docetaxel either following AC chemotherapy or in combination with docetaxel and carboplatin in patients with HER2 positive EBC following surgery.
BCIRG 006-studiet var designet til at undersøge kombinationen af Herceptin-behandling med docetaxel efter AC-kemoterapi eller i kombination med docetaxel og carboplatin hos patienter med HER2-positiv tidlig brystkræft efter operation.
The BCIRG 006 study was designed to investigate combining Herceptin treatment with docetaxel either following AC chemotherapy or in combination with docetaxel and carboplatin in patients with HER2 positive EBC following surgery.
BCR-ABL-mutation konstateret ved indtræden, n (%)b
BCR-ABL mutation detected at entry, n (%)b
Bcr-Abl-mutations status ved baseline
Bcr-Abl Mutation Status at Baseline
Bcr-Abl-tyrosinkinase (TK) såvel som adskillige TK-receptorer: Kit, receptoren for stamcellefaktoren (SCF) kodet for af c-kit proto-onkogenet, discoidin-domænereceptorerne (DDR1 og DDR2), receptoren for den kolonistimulerende faktor (CSF-1R) og receptorerne for trombocytafledte vækstfaktorer alfa og beta (PDGFR-alfa og PDGFR-beta).
Bcr-Abl tyrosine kinase (TK), as well as several receptor TKs: Kit, the receptor for stem cell factor (SCF) coded for by the c-Kit proto-oncogene, the discoidin domain receptors (DDR1 and DDR2), the colony stimulating factor receptor (CSF-1R) and the platelet-derived growth factor receptors alpha and beta (PDGFR-alpha and PDGFR-beta).
BCRP (Brystcancer-
resistance protein/ABCG2) and
BCRP og P-
ritonavir and
BCRP-, OATP1B1-, OATP1B3- og P-gp-substrater
BCRP, OATP1B1, OATP1B3 and P-gp substrates
BCRP-hæmning kan medføre øget eksponering for lægemidler som f.eks. imatinib, lapatinib, methotrexat, pitavastatin, rosuvastatin, sulfasalazin og topotecan (se pkt.
The BCRP inhibition could result in increased exposure of medicinal products such as imatinib, lapatinib, methotrexate, pitavastatin, rosuvastatin, sulfasalazine, and topotecan (see section 5.2).
BCRP.
dasabuvir.
BCVA angiver, hvor godt en person ser, efter at vedkommende har fået passende korrigerende linser.
BCVA is how well a person can see after they have been given appropriate corrective lenses.
BCVA ≥ 15 bogstaver forbedring fra baseline i år 3/afslutning (%)
BCVA ≥ 15-letter improvement from baseline at Year 3/Final (%)
BCVA ≥ 15 bogstaver forbedring fra baseline i år 3/afslutning (%)
BCVA ≥ 15-letter improvement from baseline at Year 3/Final visit (%)
BCVA ≥ 15 bogstaver forbedring fra baseline ved år 3/afslutning (%)
BCVA ≥ 15-letter improvement from baseline at Year 3/Final visit (%)
BD SafetyGlide er et varemærke tilhørende Becton Dickinson and Company og er CE-mærket: CE 0050.
BD SafetyGlide is a trademark of Becton Dickinson and Company and is CE-marked: CE 0050.
BE-1330 Rixensart Belgien
B-1330 Rixensart Belgium
BE-1330 Rixensart Belgien
BE-1330 Rixensart Belgium
Becaplermin produceres via en metode, der er kendt som ”rekombinant DNA-teknologi”: det produceres af gærceller, der har fået indsat et gen (DNA) og derved sættes i stand til at producere det humane protein Platelet Derived Growth Factor-BB.
Becaplermin is produced by a method known as ‘recombinant DNA technology’: it is made by a yeast that has received a gene (DNA), which makes it able to produce human platelet-derived growth factor-BB.
Becaplermin virker på samme måde som naturligt produceret vækstfaktor, idet det stimulerer cellevæksten og fremmer dannelsen af normalt væv til heling af sår.
Becaplermin acts in the same way as the naturally produced growth factor by stimulating cell growth and helping the growth of normal tissue for healing.
Becton, Dickinson and Company-nåle er egnede til brug sammen med Byetta-pennen..
Becton, Dickinson and Company needles are suitable to use with the Byetta pen.
Bed din familie, venner og nærmeste kollegaer om at tilkalde lægehjælp straks, hvis du ikke er i stand til at synke, eller hvis du besvimer (bliver bevidstløs).
Tell your relatives, friends and close colleagues to get medical help straight away if you are not able to swallow or if you pass out (become unconscious).
Bed din læge angive dine andre lægemidler, som kunne øge din risiko for infektion.
Please ask your physician to list your other medicines that may increase your risk of infection.
Bed din læge eller apotek om at skrive det ned (inklusive farve). hvilke dage der er dine doseringsdage.
Ask your doctor or pharmacist to write it down (including the colour). which days are your dosing days.
Bed din læge eller apotek om at skrive det ned (inklusive farve). hvilke dage, der er dine doseringsdage.
Ask your doctor or pharmacist to write it down (including the colour). which days are your dosing days.
Bed din læge eller apoteker skrive det ned (inklusive mærket) de dage, der er dine doseringsdage.
Ask your doctor or pharmacist to write it down (including the marking) which days are your dosing days.
Bed din læge eller kirurg om yderligere oplysninger om, hvilken smertestillende medicin det er forsvarligt at bruge.
Ask your doctor or surgeon for more information as to which pain medicine you can safely use.
Bed din læge, apotekspersonalet eller sygeplejersken forklare dig, hvordan du skal kassere brugte penne.
Ask your doctor, pharmacist, or nurse for instructions on throwing away used pens.
Bed din læge, apotekspersonalet eller sygeplejersken forklare dig, hvordan du skal kassere brugte sprøjter.
Ask your doctor, pharmacist, or nurse for instructions on throwing away used syringes.
Bed din læge, sygeplejerske eller apoteket om hjælp, hvis du er i tvivl om, hvordan du skal give injektionen.
If you have questions about how to inject, please ask your doctor or healthcare provider for assistance.
Bed dit apotek give dig instruktioner i at anvende sprøjten rigtigt.
Ask your pharmacist for instructions on how to use the syringe correctly.
Bed lægen om et medicinbæger til at opløse tabletterne og den orale doseringssprøjte på 10 ml eller 20 ml, hvis du ikke har disse remedier.
Ask your doctor for the medicine cup for dissolving the tablets and the 10 ml or 20 ml oral dosing syringe if you do not have these supplies.
Bed lægen om yderligere oplysninger om, hvilke smertestillende lægemidler du kan anvende sikkert.
Ask your doctor for more information as to which pain medication you can safely use.
Bedaquilin
therapeutic effect of
Bedaquilin Der er ingen tilgængelige interaktionsstudier alene med ritonavir.
Bedaquiline No interaction study is available with ritonavir only.
Bedaquilin er virksomt mod Mycobacterium tuberculosis med en MIC-værdi (minimal inhibitory concentration) for såvel lægemiddelfølsomme som lægemiddelresistente stammer (multiresistente stammer, herunder præ-ekstremt og ekstremt resistente stammer i området ≤ 0,008-0,12 mg/l.
Bedaquiline has activity against Mycobacterium tuberculosis with a minimal inhibitory concentration (MIC) for drug-sensitive as well as drug-resistant strains (multi-drug resistant including pre- extensively drug resistant strains, extensively drug resistant strains) in the range of ≤ 0.008-0.12 mg/l.
bedaquilin og lopinavir/ritonavir
bedaquiline with
bedaquilin plasma-eksponering
bedaquiline plasma exposures
Bedaquilin påvirker i mindre grad evnen til at føre motorkøretøj og betjene maskiner.
Bedaquiline has minor influence on the ability to drive and use machines.
Bedaquilin var et svagt OCT1-, OATP1B1- og OATP1B3-substrat in vitro, mens M2 ikke var.
Bedaquiline was a weak OCT1, OATP1B1 and OATP1B3 substrate in vitro, while M2 was not.
Bedaquilin var ikke et substrat for MRP2 og BCRP in vitro.
Bedaquiline was not a substrate of MRP2 and BCRP in vitro.
Bedaquilin:
Bedaquiline:
bedaquilinrelaterede
If the benefit
Bedre overlevelse blev observeret, uanset om patienterne havde tumorer, som var kategoriseret som PD-L1-negative eller PD-L1-positive (tumormembran-ekspression cut-off-niveau på 1%, 5% eller 10%).
Survival benefit was observed regardless of whether patients had tumours that were designated PD-L1 negative or PD- L1 positive (tumour membrane expression cut off of 1%, 5% or 10%).
Bedre overlevelse blev observeret, uanset om patienterne havde tumorer, som var kategoriseret som PD-L1-negative eller PD-L1-positive (tumormembranekspression cut-off-niveau på 5% eller 10%).
Survival benefit was observed regardless of whether patients had tumours that were designated PD-L1 negative or PD-L1 positive (tumour membrane expression cut off of 5% or 10%).
Bedring
Improvement
Bedring i tegn og symptomer
Improvements in signs and symptoms
Bedring i tegn og symptomer
Signs and symptoms
Bedring  90% i lægens samlede
Improvement  90% in Physician’s Global Evaluation
Bedring  90% i lægens samlede vurdering
Improvement  90% in Physician’s Global Evaluation
Bedste %-vise ændring fra baseline
Best % change from baseline (target lesions)
Bedste CCyR rate ved 12 måneder (inkluderer patienter, som opnåede CCyR på eller før den 12 måned, som respondenter) var statistisk højere for både nilotinib 300 mg og 400 mg 2 gange dagligt sammenlignet med imatinib 400 mg 1 gang dagligt, se tabel 7.
Best CCyR rate by 12 months (including patients who achieved CCyR at or before the 12 month time point as responders) was statistically higher for both nilotinib 300 mg and 400 mg twice daily compared to imatinib 400 mg once daily, see Table 7.
Bedste objektive respons (primær analyse)6
Best Overall Response – Primary analysis6
Bedste objektive responsrate a
Best overall response ratea
Bedste overordnede angiomyolipom-respons – %
Best overall angiomyolipoma response
Bedste overordnede respons
Best Overall Response (BOR)
Bedste overordnede respons på forsøgsbehandling [kemoterapi +/- strålebehandling] (%) (95 % CI)
Best overall response to study treatment [chemotherapy +/- radiotherapy] (%) (95% CI)
Bedste overordnede respons på kemoterapi (%) (95 % CI)
Best overall response to chemotherapy (%) (95% CI)
Bedste overordnede SEGA respons - (%)
Best overall SEGA response - (%)
Bedste respons (%)
Best response (%)
Bedste respons i alt (CR + PR) på kemoterapi (%) (95 %CI)
Best overall response (CR + PR) to chemotherapy (%) (95%CI)
Bedste respons i alt (CR + PR) på studiebehandling [kemoterapi +/- strålebehandling] (%) (95 %CI)
Best overall response (CR + PR) to study treatment [chemotherapy +/- radiotherapy] (%) (95%CI)
Bedste respons i alt på kemoterapi (%)
Best overall response (CR + PR) to
Bedste respons i alt på kemoterapi (%) (95% CI)
Best overall response (CR + PR) to chemotherapy (%) (95% CI)
Bedste respons i alt på studie behandling [kemoterapi +/- strålebehandling] (%) (95 %CI)
Best overall response (CR + PR) to study treatment [chemotherapy +/- chemoradiotherapy] (%) (95%CI)
Bedste respons i alt på studiebehandling
Best overall response (CR + PR) to study
Bedste respons i alt på studiebehandling [kemoterapi +/- strålebehandling] (%) (95 %CI)
Best overall response (CR + PR) to study treatment [chemotherapy +/- chemoradiotherapy] (%) (95%CI)
Bedste respons i alt på studiebehandling [kemoterapi +/- strålebehandling] (%) (95% CI)
Best overall response (CR + PR) to study treatment [chemotherapy +/- chemoradiotherapy] (%) (95%CI)
Bedste respons i alt på undersøgelsesbehandling [kemoterapi +/- strålebehandling] (%) (95 %CI)
Best overall response (CR + PR) to study treatment [chemotherapy +/- chemoradiotherapy] (%) (95% CI)
Bedste respons i alt til kemoterapi (%) (95 %CI)
Best overall response to chemotherapy (%) (95% CI)
Bedste respons i alt til kemoterapi (%) (95 %CI)
Best overall response to chemotherapy (%) (95%CI)
Bedste respons i alt til studie behandling [kemoterapi
Best overall response to study treatment [chemotherapy
Bedste respons i alt til studie behandling [kemoterapi +/- strålebehandling] (%) (95 %CI)
Best overall response to study treatment [chemotherapy +/- radiotherapy] (%) (95% CI)
Bedste respons i alt til studiebehandling [kemoterapi +/- strålebehandling] (%) (95 %CI)
Best overall response to study treatment [chemotherapy +/- radiotherapy] (%) (95% CI)
Bedste respons ialt på kemoterapi (%) (95 % CI)
Best overall response (CR + PR) to chemotherapy (%) (95% CI)
Bedste respons ialt på undersøgelsesbehandling [kemoterapi +/- strålebehandling] (%) (95 % CI)
Best overall response (CR + PR) to study treatment [chemotherapy +/- chemoradiotherapy] (%) (95%CI)
Bedste respons ialt til kemoterapi (%) (95 % CI)
Best overall response to chemotherapy (%) (95%CI)
Bedste respons ialt til undersøgelsesbehandling [kemoterapi +/- strålebehandling] (%) (95 % CI)
Best overall response to study treatment [chemotherapy +/- radiotherapy] (%) (95%CI)
Bedste respons ved
Best Response during
Bedste samlede ekstrakraniel responsrate n (%)a
BORR extra- cranial n (%)a
Bedste samlede respons
Best overall response
Bedste samlede respons (vurderet af en uafhængig komité)§
Best Overall Response (BOR) (IRC-assessed)§
Bedste samlede respons* bedømt ved IRO†
Best Overall Response* by IRO
Bedste samlede respons, n (%)
Best overall response, n (%)
Bedste samlede responsrate
Best overall response rate
Bedste samlede responsratea i hjernen Respondenter n (%) (95% konfidensintervaI)b
BORRa in brain Responders n (%) (95% CI)b
Bedste total respons på kemoterapi (%) (95% CI)
Best overall response to chemotherapy (%) (95% CI)
Bedste totale respons (%) (95% CI)
Best overall response (%) (95% CI)
Bedste tumorrespons (investigators gennemgang)
Best tumour response (investigator assessment)
Bedste tumorrespons (uvildig gennemgang)
Best tumour response (independent review)
Bedste understøttende behandling er lægemidler eller teknikker til at hjælpe patienterne, f.eks. antibiotika, smertestillende midler, transfusioner og operation, men ikke andre lægemidler mod kræft.
Best supportive care is any medicines or techniques to help patients, such as antibiotics, painkillers, transfusions and surgery, but not other cancer medicines.
Bedømmelse
Grade
Bedømmelse af resistens mod lopinavir hos patienter, hvor tidligere behandling med proteasehæmmere var mislykkedes, var karakteriseret ved analyse af isolater fra længderetningen fra 19 proteasehæmmer-erfarne forsøgspersoner i 2 fase II- og et fase III-studie, som enten oplevede ufuldstændig virologisk undertrykkelse eller viral rebound efter initial respons på Kaletra, og som udviste trinvis voksende in-vitro-resistens mellem baseline og rebound (defineret som tilsynekomst af nye mutationer eller 2-gange ændring i fænotype-følsomhed for lopinavir).
The selection of resistance to lopinavir in patients having failed prior protease inhibitor therapy was characterised by analysing the longitudinal isolates from 19 protease inhibitor-experienced subjects in 2 Phase II and one Phase III studies who either experienced incomplete virologic suppression or viral rebound subsequent to initial response to Kaletra and who demonstrated incremental in vitro resistance between baseline and rebound (defined as emergence of new mutations or 2-fold change in phenotypic susceptibility to lopinavir).
Bedømmelsen af vaccine serotype specifik effekt var 94% (95% CI: 81, 99) i intent-to-treat populationen og 97% (95% CI: 85, 100) i protokolpopulationen (fuldt immuniseret) (40 tilfælde).
The estimate of vaccine serotype specific efficacy was 94 % (95 % CI: 81, 99) in the intent-to-treat population and 97 % (95 % CI: 85, 100) in the per protocol (fully immunised) population (40 cases).